Publication: Unesbulin: A novel anti-tubulin cancer therapeutic

This research article, published in the Journal of Clinical Haematology, reports on the pharmacokinetic properties of unesbulin (PTC596), including safety and tolerability data, based on results of a Phase I, first-in-human study

Unesbulin is a novel molecule being investigated for the treatment of cancer because of its ability to reduce levels of the BMI1 protein, which prevents the survival of cancer stem cells
An overview of the mechanism of action of unesbulin and a comparison with properties of other anti-tubulin agents are presented
Results from a Phase I dose-escalation study of unesbulin in 31 patients with advanced solid tumors are discussed

Gao L, Weetall M, O’Keefe K, et al. J Clin Haematol. 2021;2(3):80–85

Register now to unlock the content

Already registered?
If not, register below

Registration

Firstname *

Surname *

Hospital *

Work email *

Specialty *

Country *

This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

*

I confirm that I am a licensed healthcare professional and would like to access this Website

*

I understand that PTC will process my personal data, including contact details, for the purposes of providing me access to this Website

I want PTC to provide, by email, updates about new content available to view on MEDhub
PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

Publication: Unesbulin: A novel anti-tubulin cancer therapeutic

Authenticating...

COMING SOON